Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GN001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
NCT07910708Phase 1Recruiting
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of GN001 in B-cell non-Hodgkin lymphoma (B-NHL) and acute lymphoblastic leukemia (ALL) (4 arms). Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Aug 2026; status: recruiting.
02
Drugs
GN001
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07910708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07910708.